CorMedix (CRMD) shares rose by more than 16% in Tuesday's premarket activity after it reported preliminary Q4 net revenue of $31 million.
Analysts surveyed by FactSet expected sales of $19.7 million.
The biopharmaceutical firm also said it has more than $25 million worth of orders scheduled for delivery in Q1.
The company also reported preliminary cash and short-term investments of about $52 million, as of Dec. 31.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.